Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medacta Group SA ( (CH:MOVE) ) has issued an announcement.
Medacta Group SA reported a significant increase in its adjusted EBITDA margin to 29.6% in the first half of 2025, with revenues reaching €344.1 million, a 19.8% rise in constant currency. The company’s growth was driven by innovations across all business lines, including the launch of new products like the NextAR Rod Optimizer and MyImplant for Hip, as well as the acquisition of Parcus Medical, which expanded its sports medicine portfolio. Medacta’s strategic initiatives and expansion efforts have positioned it for continued success, with notable revenue growth in key regions such as North America and Asia Pacific, and across all product lines, particularly in knee and extremities.
The most recent analyst rating on (CH:MOVE) stock is a Hold with a CHF151.00 price target. To see the full list of analyst forecasts on Medacta Group SA stock, see the CH:MOVE Stock Forecast page.
More about Medacta Group SA
Medacta Group SA operates in the medical technology industry, focusing on orthopedic and spine surgery solutions. The company is known for its innovative surgical techniques and products, such as the Kinematic Alignment for knee replacement and the NextAR Augmented Reality Surgical Platform, which enhance patient outcomes and surgical efficiency. Medacta also provides custom-made implant solutions and has a strong presence in the global orthopedic community.
YTD Price Performance: 34.25%
Average Trading Volume: 9,564
Technical Sentiment Signal: Buy
Current Market Cap: CHF2.85B
For an in-depth examination of MOVE stock, go to TipRanks’ Overview page.